TEVA Q1 2021 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.0B-8.6% YoY

Gross Profit

$1.9B47.2% margin

Operating Income

$434M10.9% margin

Net Income

$77M1.9% margin

EPS (Diluted)

$0.07

QoQ Revenue Growth

-10.6%

Cash Flow

Operating Cash Flow

-$405M

Free Cash Flow

-$555M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$49.0B

Total Liabilities

$38.0B

Stockholders' Equity

$10.0B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.0B	$4.4B	-8.6%
Gross Profit	$1.9B	$2.1B	-9.0%
Operating Income	$434M	$191M	+127.2%
Net Income	$77M	$69M	+11.6%

Revenue Segments

Product

$3.5B87%

Distribution Service

$308M8%

Product and Service, Other

$162M4%

License

$49M1%

Geographic Segments

North America Segment

$2.0B54%

Europe Segment

$1.2B33%

International Markets

$490M13%